176 related articles for article (PubMed ID: 38212401)
1. Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension.
Grech O; Mitchell JL; Lyons HS; Yiangou A; Thaller M; Tsermoulas G; Brock K; Mollan SP; Sinclair AJ
Eye (Lond); 2024 May; 38(7):1374-1379. PubMed ID: 38212401
[TBL] [Abstract][Full Text] [Related]
2. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial.
Mitchell JL; Lyons HS; Walker JK; Yiangou A; Grech O; Alimajstorovic Z; Greig NH; Li Y; Tsermoulas G; Brock K; Mollan SP; Sinclair AJ
Brain; 2023 May; 146(5):1821-1830. PubMed ID: 36907221
[TBL] [Abstract][Full Text] [Related]
3. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus.
Botfield HF; Uldall MS; Westgate CSJ; Mitchell JL; Hagen SM; Gonzalez AM; Hodson DJ; Jensen RH; Sinclair AJ
Sci Transl Med; 2017 Aug; 9(404):. PubMed ID: 28835515
[TBL] [Abstract][Full Text] [Related]
4. Preclinical update on regulation of intracranial pressure in relation to idiopathic intracranial hypertension.
Eftekhari S; Westgate CSJ; Uldall MS; Jensen RH
Fluids Barriers CNS; 2019 Nov; 16(1):35. PubMed ID: 31767019
[TBL] [Abstract][Full Text] [Related]
5. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451
[TBL] [Abstract][Full Text] [Related]
6. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.
Ishøy PL; Knop FK; Broberg BV; Bak N; Andersen UB; Jørgensen NR; Holst JJ; Glenthøj BY; Ebdrup BH
Diabetes Obes Metab; 2017 Feb; 19(2):162-171. PubMed ID: 27717222
[TBL] [Abstract][Full Text] [Related]
7. Idiopathic intracranial hypertension: expanding our understanding.
Markey K; Hutchcroft C; Emsley H
Curr Opin Neurol; 2023 Dec; 36(6):622-630. PubMed ID: 37865852
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial.
Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Diamant M; Pieters-van den Bos IC; van Raalte DH; Cahen DL
Diabetes Obes Metab; 2016 Mar; 18(3):281-8. PubMed ID: 26640129
[TBL] [Abstract][Full Text] [Related]
9. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
[TBL] [Abstract][Full Text] [Related]
10. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.
Ishøy PL; Knop FK; Broberg BV; Baandrup L; Fagerlund B; Jørgensen NR; Andersen UB; Rostrup E; Glenthøj BY; Ebdrup BH
BMJ Open; 2014 Jan; 4(1):e004158. PubMed ID: 24401727
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of diurnal and postural intracranial pressure employing telemetric monitoring in idiopathic intracranial hypertension.
Mitchell JL; Buckham R; Lyons H; Walker JK; Yiangou A; Sassani M; Thaller M; Grech O; Alimajstorovic Z; Julher M; Tsermoulas G; Brock K; Mollan SP; Sinclair AJ
Fluids Barriers CNS; 2022 Nov; 19(1):85. PubMed ID: 36320018
[TBL] [Abstract][Full Text] [Related]
12. Headache attributed to idiopathic intracranial hypertension and persistent post-idiopathic intracranial hypertension headache: A narrative review.
Mollan SP; Grech O; Sinclair AJ
Headache; 2021 Jun; 61(6):808-816. PubMed ID: 34106464
[TBL] [Abstract][Full Text] [Related]
13. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
14. Incidence and predictors of dural venous sinus pressure gradient in idiopathic intracranial hypertension and non-idiopathic intracranial hypertension headache patients: results from 164 cerebral venograms.
Levitt MR; Hlubek RJ; Moon K; Kalani MY; Nakaji P; Smith KA; Little AS; Knievel K; Chan JW; McDougall CG; Albuquerque FC
J Neurosurg; 2017 Feb; 126(2):347-353. PubMed ID: 26967777
[TBL] [Abstract][Full Text] [Related]
15. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database.
Best JH; Hoogwerf BJ; Herman WH; Pelletier EM; Smith DB; Wenten M; Hussein MA
Diabetes Care; 2011 Jan; 34(1):90-5. PubMed ID: 20929995
[TBL] [Abstract][Full Text] [Related]
16. Idiopathic Intracranial Hypertension After Abrupt Cessation of Medication: A Case Report of Abrupt Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Cessation and Review of the Literature.
Heckel B
Curr Pain Headache Rep; 2024 Jun; 28(6):453-456. PubMed ID: 38573570
[TBL] [Abstract][Full Text] [Related]
17. Comparative observational study on the clinical presentation, intracranial volume measurements, and intracranial pressure scores in patients with either Chiari malformation Type I or idiopathic intracranial hypertension.
Frič R; Eide PK
J Neurosurg; 2017 Apr; 126(4):1312-1322. PubMed ID: 27341045
[TBL] [Abstract][Full Text] [Related]
18. Telemetric monitoring in idiopathic intracranial hypertension demonstrates intracranial pressure in a case with sight-threatening disease.
Mitchell JL; Mollan SP; Tsermoulas G; Sinclair AJ
Acta Neurochir (Wien); 2021 Mar; 163(3):725-731. PubMed ID: 33411042
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of optical coherence tomography for intracranial pressure in idiopathic intracranial hypertension.
Skau M; Yri H; Sander B; Gerds TA; Milea D; Jensen R
Graefes Arch Clin Exp Ophthalmol; 2013 Feb; 251(2):567-74. PubMed ID: 22592348
[TBL] [Abstract][Full Text] [Related]
20. Osmolality of Cerebrospinal Fluid from Patients with Idiopathic Intracranial Hypertension (IIH).
Wibroe EA; Yri HM; Jensen RH; Wibroe MA; Hamann S
PLoS One; 2016; 11(1):e0146793. PubMed ID: 26808050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
